Does Bactrim Cover MRSA?
Yes, Bactrim (trimethoprim-sulfamethoxazole) does provide coverage for MRSA and is specifically recommended by IDSA guidelines as a first-line oral antibiotic option for community-acquired MRSA skin and soft tissue infections. 1
Guideline-Based Recommendations
The 2011 IDSA guidelines explicitly list trimethoprim-sulfamethoxazole (TMP-SMX) as an A-II level recommendation for empirical coverage of CA-MRSA in outpatients with skin and soft tissue infections (SSTIs). 1 The guidelines place TMP-SMX on equal footing with clindamycin, tetracyclines (doxycycline/minocycline), and linezolid for this indication.
When to Use Bactrim for MRSA:
Outpatient settings:
- Purulent cellulitis (cellulitis with purulent drainage but no drainable abscess)
- Abscesses requiring antibiotic therapy (severe/extensive disease, systemic symptoms, immunocompromised patients, difficult-to-drain locations)
- Duration: 5-10 days, individualized based on clinical response 1
Important limitation: When coverage for both β-hemolytic streptococci AND CA-MRSA is needed, TMP-SMX must be combined with a β-lactam (e.g., amoxicillin) since it does not adequately cover streptococcal species. 1
Critical Caveats for Severe Infections
For severe/invasive MRSA infections, Bactrim is NOT the preferred agent. A 2015 randomized controlled trial directly comparing high-dose TMP-SMX (320/1600 mg twice daily) versus vancomycin for severe MRSA infections found that TMP-SMX failed to meet non-inferiority criteria. 2 Treatment failure occurred in 38% of TMP-SMX patients versus 27% with vancomycin (risk ratio 1.38). The difference was particularly pronounced in bacteremic patients, where 34% died with TMP-SMX versus 18% with vancomycin. 2
Do not use Bactrim for:
- Bacteremia/bloodstream infections
- Hospitalized patients with complicated SSTIs (use IV vancomycin, linezolid, daptomycin, or telavancin instead) 1
- Left-sided endocarditis
- Meningitis
- Severe systemic infections requiring hospitalization
FDA Labeling Considerations
The FDA label for Bactrim does NOT list MRSA as an approved indication. 3 The approved organisms include E. coli, Klebsiella, Enterobacter, Proteus species, Shigella, H. influenzae, S. pneumoniae, and P. jirovecii—but notably, Staphylococcus aureus is absent from the indication list. 3 This represents off-label use supported by guidelines and clinical evidence.
Resistance Patterns - A Growing Concern
Monitor local resistance patterns carefully. Recent surveillance data (2012-2018) shows increasing rates of TMP-SMX resistance among MRSA isolates in the United States. 4 Resistance is particularly high in:
- Institutions serving HIV-positive populations (due to chronic Pneumocystis prophylaxis exposure)
- Areas with Brazilian MRSA clones (higher TMP-SMX resistance than Iberian clones) 5
Small colony variants (SCVs) of S. aureus can exhibit TMP-SMX resistance that may not be detected by routine susceptibility testing. 6 If clinical failure occurs despite reported susceptibility, consider this possibility.
Practical Algorithm
For uncomplicated CA-MRSA skin infections (outpatient):
- If purulent drainage present → Culture and start empiric TMP-SMX
- If concern for streptococcal co-infection → Add amoxicillin to TMP-SMX
- Reassess at 48-72 hours for clinical improvement
- Adjust based on culture results and local resistance patterns
For severe/invasive MRSA:
- Hospitalize and initiate IV vancomycin (first-line)
- Do NOT use TMP-SMX as monotherapy
- Consider combination therapy only in specific circumstances with infectious disease consultation
Bottom line: Bactrim covers MRSA effectively for mild-to-moderate outpatient skin infections but should be avoided for bacteremia, severe infections, or hospitalized patients where vancomycin remains the gold standard. 1, 2